Immune Design Moving Cancer Immunotherapy Platform into Clinic
As further proof that cancer immunotherapy is no longer the biopharma pariah of several years ago, Immune Design Corp. closed a $49 million Series C round to advance its lead candidates into the clinic.
The financing, which nearly doubles the Seattle-based biotech’s $52 million venture capital to date, includes $32.5 million up front, with the remaining $16.5 million anticipated after the firm gathers Phase I data, said President and CEO Carlos Paya. Immune Design aims to move into the clinic next year.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST